Hereditary hearing loss, predominantly attributed to mutations in the GJB2 gene, constitutes a significant global health issue, with the c.235delC mutation being the most prevalent pathogenic allele in East Asian populations. Existing interventions, such as hearing aids and cochlear implants, mitigate symptoms but fail to correct the underlying genetic defects, highlighting the need for precise therapeutic...
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable clinical change; this is early-stage in vitro (lab cell) work and years away from human trials, but it represents a credible preclinical step toward gene therapy for GJB2-related hearing loss.
Demonstrating precise in vitro correction of the most prevalent hereditary deafness mutation with prime editing advances the gene therapy pipeline for a condition that currently has no curative treatment.
- 01Prime editing precisely corrected the GJB2 c.235delC mutation—the leading cause of hereditary hearing loss—in laboratory cell cultures.
- 02Prime editing offers higher precision than earlier CRISPR approaches, reducing unintended DNA changes (off-target edits).
- 03Study is entirely in vitro (cells in a dish); no animal or human data are reported.
- 04Published in the journal Gene Therapy.
- 05GJB2 mutations account for a large proportion of congenital genetic deafness globally.
Prime editing can precisely correct the GJB2 c.235delC mutation in vitro without significant off-target effects.
studypartially supportedGJB2 c.235delC is the most prevalent mutation causing hereditary hearing loss.
studysupported- PMID
- 42562992
- DOI
- 10.1038/s41434-026-00638-w.
- Journal
- Gene Therapy
- Publication type
- research_article
- Evidence level
- na
- Population
- In vitro cell cultures carrying the GJB2 c.235delC mutation
- Intervention
- Prime editing to correct GJB2 c.235delC mutation
- Comparator
- Uncorrected control cells
Primary outcomes
Efficiency of GJB2 c.235delC mutation correction by prime editing; Off-target editing rate